Turning Point Therapeutics (TPTX) Peer Comparison

$76.01

$0.00 (0.00%)

As on 07-Sep-2022 09:30EDT

Market cap

$3,806 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

4.8

Div. Yield

0 %

Edit

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Market cap ($ Mln)	3,806	54
Revenue ($ Mln)	1	--
Net Profit ($ Mln)	-342.31	-24.19
Net Margin (%)	-33,130.60	-6,313.55
RoE (%)	-39.18	-30.08
Price to Earnings	--	--
Price-To-Book	4.80	0.72

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Operating Revenue	1.03	0.00
Cost of Revenue	0.00	0.00
Gross Profit	30.83	--
Operating Expenses	345.60	23.03
Operating Profit (EBIT)	-344.59	-25.47
Other Income	0.00	0.38
Profit before Tax	-342.31	-24.19
Provision for Tax	0.00	0.00
Profit after Tax (Net Income)	-342.31	-24.19
Minority Interest	0.00	0.00
Consolidated Profit	-342.31	-24.19

Liabilities ($ Mln)

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Shareholder's Funds	793.02	74.14
Minority Interest	0.00	0.00
Non-Current Liabilities	0.89	0.40
Current Liabilities	49.42	5.62
Total Liabilities	1,003.46	110.26

Assets ($ Mln)

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Non-Current Assets	11.67	1.14
Current Assets	831.67	79.02
Total Assets	1,003.46	110.26
Total Debt*	4.94	0.03
Net Current Assets	782.24	73.40

Cashflow ($ Mln)

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Cash From Operating Activities	-153.89	-23.56
Cash Flow from Investing Activities	5.46	-72.54
Cash from Financing Activities	24.00	104.38
Net Cash Inflow / Outflow	--	80.82

Ratios

Profitability Ratios

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
ROCE (%)	-22.81	-47.71
ROE (%)	-39.18	-30.08
ROA (%)	-33.77	-25.00
EBIT Margin (%)	-33,130.60	--
Net Margin (%)	-33,130.60	-6,313.55
Cash Profit Margin (%)	-0.01	--

Growth Ratios

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Revenue Growth (%)	-98.13	--
EBIT Growth (%)	-118.23	-7.83
Net Profit Growth (%)	-118.23	7.25
EPS Growth (%)	-100.15	25.45
Book Value Growth (%)	-27.20	-23.16

Valuation Ratios

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Price / Earnings	-9.88	-8.23
Price / Book Value	2.45	2.34
Dividend Yield (%)	--	--
EV/EBITDA	-5.85	-4.82
Market Cap ($ Cr)	--	--

Solvency Ratios

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.01	0.00
Current Ratio	16.83	14.06
Quick Ratio	16.83	14.06
Interest Coverage	--	-396.51

Operating Efficiency Ratios

	Turning Point Therapeutics (TPTX)	Tyme Technologies (TYME)
Debtors to sales (%)	0.00	--
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly